Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
after starting the IV routine
Mol Genet Metab 126:413415
METAOD005: A Phase IIb (randomized, double-blind, placebo-controlled) study to assess the efficacy (reduction in body weight), safety and tolerability of 12 weeks treatment with daily doses (1, 5, 10, 20 or 30 mg AOD9604) administered orally (capsules) in 300 healthy, clinically obese males, and females of non-child bearing potential, with a BMI 35 kg/m 2
Researchers analyze its structure and peptide-related interactions within experimental research models
the measure is co-financed with tax funds on the basis of the budget passed by the Saxon state parliament (to M.F.), Deutsche Forschungsgemeinschaft (FE 1236/5-1 to M.F.) and Bundesministerium fr Bildung und Forschung (01EJ2205A, FERROPath to M.F.)
10.1038/s41572-018-0004-9 16 ChatterjeeP
US$ 28.36
US$ 24.93
.png)
.png)
US$ 24.72
US$ 29.33
US$ 26.48
US$ 27.80
US$ 24.46
US$ 26.19
US$ 26.17
US$ 21.97
